GoodRx, a resource for healthcare savings and information, is working with Sanofi, a company that specializes in diabetes care, to offer people living with diabetes access to Lantus (insulin glargine ...

GoodRx is teaming up with Sanofi to offer consumers access to its most prescribed insulin, Lantus, for $35 at thousands of pharmacies nationwide. All Americans with a valid prescription, regardless of ...

Telehealth platform GoodRx has become the latest company to offer people with diabetes access to insulin for $35 per month— regardless of whether they have insurance. GoodRx said in a statement that ...

Limited time only. Minimum spend of $350. Selected products only. For full terms and conditions please visit the website. This offer is valid on Ozempic, Mounjaro KwikPen, Wegovy, Rybelsus, and ...

Effective yesterday, patients with diabetes can obtain a 30-day supply of Lantus for $35 at the 70,000 pharmacies that accept GoodRx coupons, including CVS and Walgreens locations. Drugmakers have ...

GoodRx announced Thursday morning that it is working with Sanofi on a program to offer one of its leading insulin products to consumers for $35 per month. By visiting ...

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, today announced it is working with Sanofi (NASDAQ: SNY), a global leader in ...

More Americans with diabetes will get a break on their insulin costs in 2024. Sanofi is joining the nation’s two other major insulin manufacturers in offering either price caps or savings programs ...

Tresiba (insulin degludec) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to treat type 1 and type 2 diabetes in ...

Amid consumer angst and political pressure over the cost of life-saving insulin, Sanofi announced Thursday it would slash the price of its most-prescribed insulin, Lantus. Sanofi said it will cut the ...